Browsing by Author "Yavuz, Veysel"

Now showing 1 - 9 of 9

Baseline Clinical Characteristics of Patients from the Evaluation of Treatment Safety in Patients with Atrial Fibrillation on Edoxaban Therapy in Real-Life in TüRkiye Study
(Kare Publ, 2026) Yavuz, Veysel; Turk, Ugur Onsel; Arslan, Ugur; Kocabas, Umut; Akgun, Didar Elif; Coner, Ali; Kurşun, Mustafa; Uguz, Berat
Objective: A post-authorization safety study with a prospective design focusing on the safety of edoxaban treatment in Türkiye has not yet been conducted. The Evaluation of Treatment Safety in Patients with Atrial Fibrillation on Edoxaban Therapy in Real-Life in TüRkiye (ETAF-TR) study was designed to evaluate the safety and effectiveness of edoxaban treatment in atrial fibrillation (AF). The baseline results of the ETAF-TR study describe the demographic, clinical, and laboratory characteristics of the study population. Method: The ETAF-TR study (NCT04594915) is a prospective, national, multicenter, observational, post-authorization safety study conducted in 50 outpatient cardiology clinics. Results: Overall, 1,053 patients with AFtreated with edoxaban forstroke prevention were enrolled in the study between August 2020 and May 2022. The mean age of the study population was 70.1 +/- 11.3 years, and 59.0% of the patients were female. Mean CHA2DS2-VASc (Congestive heart failure, Hypertension, Age >= 75 years, Diabetes, Stroke/TIA/thromboembolism, Vascular disease, Age 65-74 years, Sex category) and HAS-BLED scores (Hypertension, Abnormal renal/ liver function, Stroke, Bleeding history/predisposition, Labile INR, Elderly, Drugs/alcohol) were 3.5 and 1.6, respectively. Of the 1,053 patients, 843 (80.1%) received standard-dose edoxaban and 210 (19.9%) received reduced-dose edoxaban. Of the 1,053 patients, 38 (3.6%) had off-label use of edoxaban therapy. Among the remaining 1,015 patients, 834 (82.2%) received an appropriate dose of edoxaban and 181 (17.8%) received an inappropriate dose of edoxaban according to the Summary of Product Characteristics (SmPC) criteria. Conclusion: Edoxaban has been used in a wide spectrum of patients with AF in daily routine practice, with good overall adherence to the SmPC. As the largest national pharmacovigilance study to date, the ETAF-TR study will provide detailed insight into the safety of edoxaban treatment.
Demographic, Clinical, and Disease Characteristics of Patients With Atrial Fibrillation on Edoxaban Therapy According To the Stroke Risk: a Report From Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life Data
(Kare Publ, 2022) Akgun, Didar Elif; Avci, Eyup; Yavuz, Veysel; Isik, Turgay; Topuz, Sahin; Uludag, Demet Menekse Gerede; Totan, Sahin
[Abstract Not Available]
Incidence and Predictors of Clinical Outcomes in Real-Life Patients With Atrial Fibrillation Treated With Oral Factor Xa Inhibitors: the Follow-Up Results of the Anatolia-Af Study
(Wiley, 2025-01) Kocabas, Umut; Ergin, Isil; Sonmez, Sadi Can; Yavuz, Veysel; Murat, Selda; Ozdemir, Ibrahim Halil; Kivrak, Tarik
ObjectiveThe main objective of this study is to determine the incidence and predictors of clinical outcomes in patients with AF treated with factor Xa inhibitors in a real-world setting.MethodsThe present study was a multicentre and observational study that included patients with AF who were treated with factor Xa inhibitors. The primary outcome was the composite of ischemic stroke, TIA, systemic embolism, major bleeding, and all-cause mortality.ResultsA total of 1162 patients from 26 cardiology centers were included in this study, with a median age of 72 years. During the median 12-month follow-up period, the primary outcome occurred in 195 patients (16.8%). Treatment with rivaroxaban compared with apixaban and edoxaban showed a lower rate of ischemic stroke, TIA, and/or systemic embolism (2.2% vs. 4.7% vs. 6.5%, respectively, p = 0.014). The major bleeding rate was similar between all three factor Xa inhibitors. The all-cause mortality rate in the rivaroxaban group was lower compared with the apixaban and edoxaban groups (9.8% vs. 15.1% vs. 12.4%, respectively, p = 0.042). Overall, the frequency of primary outcome was 13.8%, 19.6%, and 20.6% for patients treated with rivaroxaban, apixaban, and edoxaban, respectively (p = 0.019). Older age, male sex, low body weight, high bleeding risk, heart failure, hypertension, liver failure, and treatment with apixaban 2.5 mg b.i.d. were independently associated with the development of primary outcome.ConclusionThe follow-up data from the ANATOLIA-AF study provides detailed data about the incidence and independent predictors of adverse clinical outcomes in patients with AF treated with factor Xa inhibitor treatment.
Citation - WoS: 5
Citation - Scopus: 2
Prevalence and Associated Factors of Inappropriate Dosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: the Anatolia-Af Study
(Springer, 2022-12-17) Kocabas, Umut; Ergin, Isil; Yavuz, Veysel; Murat, Selda; Ozdemir, Ibrahim; Genc, Omer; Altin, Cihan; Ozcalik, Emre
Purpose Inappropriate dosing of direct oral anticoagulants is associated with an increased risk of stroke, systemic embolism, major bleeding, cardiovascular hospitalization, and death in patients with atrial fibrillation. The main goal of the study was to determine the prevalence and associated factors of inappropriate dosing of direct oral anticoagulants in real-life settings.Methods This study was a multicenter, cross-sectional, observational study that included 2004 patients with atrial fibrillation. The study population was recruited from 41 cardiology outpatient clinics between January and May 2021. The main criteria for inappropriate direct oral anticoagulant dosing were defined according to the recommendations of the European Heart Rhythm Association.Results The median age of the study population was 72 years and 58% were women. Nine-hundred and eighty-seven patients were prescribed rivaroxaban, 658 apixaban, 239 edoxaban, and 120 dabigatran. A total of 498 patients (24.9%) did not receive the appropriate dose of direct oral anticoagulants. In a logistic regression model, advanced age, presence of chronic kidney disease and permanent atrial fibrillation, prescription of reduced doses of direct oral anticoagulants or edoxaban treatment, concomitant use of amiodarone treatment, and non-use of statin treatment were significantly associated with potentially inappropriate dosing of direct oral anticoagulants.Conclusion The study demonstrated that the prevalence of inappropriate direct oral anticoagulant dosing according to the European Heart Rhythm Association recommendations was 24.9% in patients with atrial fibrillation. Several demographic and clinical factors were associated with the inappropriate prescription of direct oral anticoagulants.
Citation - WoS: 1
Prevalence and Associated Factors of Inappropriate Dosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: the Anatolia-Af Study (dec, 10.1007/S10557-022-07409-w, 2022)
(Springer, 2023-01-19) Kocabas, Umut; Ergin, Isil; Yavuz, Veysel; Murat, Selda; Ozdemir, Ibrahim; Genc, Omer; Altin, Cihan; Özçalık, Emre
[Abstract Not Available]
Prevalence and Associated Factors of Inappropriate Dosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: the Anatolia-Af Study [pp. 59-61]
(Kare Publ, 2022-12-17) Kocabas, Umut; Ergin, Isil; Yavuz, Veysel; Murat, Selda; Ozdemir, Ibrahim; Genc, Omer; Altin, Cihan; Okar, Sefa
[Abstract Not Available]
Citation - WoS: 13
Citation - Scopus: 14
Real-World Data on Empagliflozin and Dapagliflozin Use in Patients With Heart Failure: the Red-Heart Study
(Wiley Periodicals, Inc, 2024-09-28) Kocabaş, Umut; Ergin, Işıl; Yavuz, Veysel; Altın, Cihan; Kaplan, Mehmet; Oztekin, Guelsuem Meral Yilmaz; Dogdus, Mustafa; Turk, Ugur Onsel; Yılmaz Öztekin, Gülsüm Meral
Aims: We aimed to determine the use of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and to identify clinical factors associated with their use in patients with heart failure (HF) in a real-life setting. Methods: Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED-HEART study is a multicentre, cross-sectional and observational study that included HF patients in the outpatient setting regardless of ejection fraction from 19 cardiology centres between August 2023 and December 2023. Results: The study population consisted of 1923 patients with HF, predominantly men (61.2%), with a median age of 66 (range: 19-101) years. Overall, 925 patients (48.1%) were receiving SGLT2is. Among the study population, 22.1% had HF with preserved ejection fraction, 21.5% had HF with mildly reduced ejection fraction, 56.4% had HF with reduced ejection fraction and the use of SGLT2is was 42.0%, 47.9% and 50.6% in each group, respectively (P = 0.012). The use of SGLT2is was 76.6% in patients with HF and diabetes, 19.8% in patients with HF and chronic kidney disease and 26.8% in patients without diabetes and chronic kidney disease (P < 0.001). Higher education level [odds ratio (OR): 1.80; 95% confidence interval (CI): 1.06-3.05; P = 0.027], higher household income (OR: 3.46; 95% CI: 1.27-9.42; P = 0.015), New York Heart Association functional class IV (OR: 2.72; 95% CI: 1.16-6.35; P = 0.021), diabetes (OR: 9.42; 95% CI: 6.72-13.20; P < 0.001), the use of angiotensin receptor-neprilysin inhibitors (ARNis) (OR: 4.09; 95% CI: 2.39-7.01; P < 0.001), the use of mineralocorticoid receptor antagonists (MRAs) (OR: 2.02; 95% CI: 1.49-2.75; P < 0.001), the use of loop diuretics (OR: 1.62; 95% CI: 1.18-2.22; P = 0.003) and the use of thiazide diuretics (OR: 1.72; 95% CI: 1.30-2.29; P < 0.001) were independently associated with the use of SGLT2is. Conversely, atrial fibrillation (OR: 0.63; 95% CI: 0.45-0.88; P = 0.008), chronic kidney disease (OR: 0.53; 95% CI: 0.37-0.76; P = 0.001), the use of dihydropyridine calcium channel blockers (OR: 0.68; 95% CI: 0.48-0.98; P = 0.042) and the use of statins (OR: 0.67; 95% CI: 0.49-0.91; P = 0.010) were independently associated with the non-use of SGLT2is. Conclusions: The RED-HEART study provided comprehensive real-world data about implementing SGLT2is in patients with HF. These results suggest that there is a need for organized action and close collaboration between healthcare providers to improve the implementation of SGLT2is, especially in patients with HF with preserved ejection fraction and chronic kidney disease.
Real-World Evaluation of Anticoagulant Treatment Patterns in Patients With Atrial Fibrillation: Data From Multicenter Rota Study [2022]
(Kare Publ, 2023) Kocabas, Umut; Ergin, Isil; Yavuz, Veysel; Murat, Selda; Ozdemir, Ibrahim; Genc, Omer; Altin, Cihan; Özçalık, Emre; Şengör, Büşra Güvendi; Sen, Taner; Kaplan, Mehmet; Dal, Ahmet; Dogdus, Mustafa; Şahin, Şeyda
[Abstract Not Available]
Citation - WoS: 3
Citation - Scopus: 3
Real-World Evaluation of Anticoagulant Treatment Patterns in Patients With Atrial Fibrillation: Data From Multicenter Rota Study [2023]
(Kare Publ, 2023) Kocabas, Umut; Ergin, Isil; Yavuz, Veysel; Murat, Selda; Özdemir, İbrahim; Genç, Ömer; Altın, Cihan
Objective: Oral anticoagulant therapy is the cornerstone of atrial fibrillation management to prevent stroke and systemic embolism. However, there is limited real-world information regarding stroke and systemic embolism prevention strategies in patients with atrial fibrillation. The aim of the ROTA study is to obtain the real-world data of anticoagulant treatment patterns in patients with atrial fibrillation. Materials and Methods: The ROTA study is a prospective, multicenter, and observational study that included 2597 patients with atrial fibrillation. The study population was recruited from 41 cardiology outpatient clinics between January 2021 and May 2021.Results: The median age of the study population was 72 years (range: 22-98 years) and 57.4% were female. The median CHA2DS2-VASc and HAS-BLED scores were 4 (range: 0-9) and 1 (range: 0-6), respectively. Vitamin K antagonists and direct oral anticoagulants were used in 15.9% and 79.4% of patients, respectively. The mean time in therapeutic range was 52.9% for patients receiving vitamin K antagonists, and 76% of those patients had an inadequate time in therapeutic range with <70%. The most common prescribed direct oral anticoagulants were rivaroxaban (38.1%), apixaban (25.5%), and edoxaban (11.2%). The rate of overuse of vitamin K antagonists and direct oral anticoagulants was high (76.1%) in patients with low stroke risk, and more than one-fourth of patients on direct oral anticoagulant therapy were receiving a reduced dose of direct oral anticoagulants. Among patients who were on direct oral anticoagulant treatment, patients with apixaban treatment were older, had higher CHA2DS2- VASc and HAS-BLED scores, and had lower creatinine clearance than the patients receiving other direct oral anticoagulants.Conclusions: The ROTA study provides important real-world information about anticoagulant treatment patterns in patients with atrial fibrillation.